Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

South Korea Implements IVD Regulation Amid Renewed COVID-19 Scare

Executive Summary

South Korea, one of the first countries to be hit by the spread of COVID-19 from China, has implemented new standalone IVD regulations.

You may also be interested in...



South Korea Roundup: Augmented Reality Device Guidelines, Digital, UDI And IVD Updates

The devices regulator has sought private sector input in updating AR/VR guidelines, but needs to do more on telemedicine integration. Mixed experiences are reported on UDI and the new IVD regulation.

Asian Medtech Associations Reg Networking: COVID-19 Dominates As Medtechs Seek Return To Normality – Part One

The Asian Medtech Associations Regulatory Networking discussions this month centered on strategies to control COVID-19 in Thailand, Singapore, South Korea, Indonesia and Vietnam. This editorial feature is hosted by Medtech Insight, along with the Asia Regulatory and Quality Consultancy and the Asia Regulatory Professional Association. This is the first of two articles from the discussions.

Fact File: European COVID-19 Focus Shifts To Managing The ‘New Normal’

The evolution of how and where patients receive their care has received an unexpected boost from the COVID-19 crisis. Coronavirus volume testing challenges persist, but the global medtech industry is now looking beyond the crisis toward a return to “normal” business.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT142223

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel